By Dominic Chopping
STOCKHOLM--Swedish buyout group EQT and French pharmaceutical major Sanofi co-led a $135 million series B financing round in Spanish biotech company SpliceBio.
EQT co-led the funding round with Sanofi Ventures, while Roche Venture Fund and all existing investors also participated.
SpliceBio is developing therapies for genetic diseases using protein splicing technology.
Proceeds from the funding will support the company's phase 1/2 clinical development of SB-007, a therapy being developed to treat Stargardt disease, a genetic eye disorder that causes progressive vision loss and blindness.
Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other therapeutic areas.
Daniela Begolo, Managing Director at EQT Life Sciences, will join the SpliceBio board of directors.
Existing investors in SpliceBio include New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
June 11, 2025 04:10 ET (08:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。